Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT2C Agonists.

Kim J, Kim YJ, Londhe AM, Pae AN, Choo H, Kim HJ, Min SJ.

Molecules. 2019 Sep 5;24(18). pii: E3234. doi: 10.3390/molecules24183234.

2.

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD.

Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar.

3.

Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.

Kim DS, Lee J, Londhe AM, Kadayat TM, Joo J, Hwang H, Kim KH, Pae AN, Chin J, Cho SJ, Kang H.

Bioorg Med Chem. 2018 Aug 15;26(15):4382-4389. doi: 10.1016/j.bmc.2018.06.044. Epub 2018 Jul 20.

PMID:
30054191
4.

Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.

Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ.

Eur J Med Chem. 2017 Dec 1;141:657-675. doi: 10.1016/j.ejmech.2017.10.003. Epub 2017 Oct 4.

PMID:
29107425
5.

Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.

Kim T, Son WS, Morshed MN, Londhe AM, Jung SY, Park JH, Park WK, Lim SM, Park KD, Cho SJ, Jeong KS, Lee J, Pae AN.

Eur J Med Chem. 2017 Dec 1;141:240-256. doi: 10.1016/j.ejmech.2017.09.033. Epub 2017 Sep 21.

PMID:
29031071
6.

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction.

Park I, Londhe AM, Lim JW, Park BG, Jung SY, Lee JY, Lim SM, No KT, Lee J, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):929-941. doi: 10.1007/s10822-017-0067-9. Epub 2017 Sep 14.

PMID:
28913661
7.

In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.

Park I, Hwang YJ, Kim T, Viswanath ANI, Londhe AM, Jung SY, Sim KM, Min SJ, Lee JE, Seong J, Kim YK, No KT, Ryu H, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):877-889. doi: 10.1007/s10822-017-0052-3. Epub 2017 Sep 6.

PMID:
28879500

Supplemental Content

Loading ...
Support Center